Kalaris Therapeutics Inc (KLRS)
Kalaris Therapeutics Inc. (NASDAQ: KLRS) is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for common retinal diseases. Its lead candidate, TH103, is an anti-VEGF therapy in Phase 1b/2 development for neovascular age-related macular degeneration (nAMD) and other exudative and neovascular retinal conditions. The company, formerly known as Theia Therapeutics, Inc., adopted its current name in May 2024. Founded in 2019, Kalaris Therapeutics is headquartered in Berkeley Heights, New Jersey. The listed security is common stock of the company.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-KLRS
|
$3.90
|
20.3% Upside
|
Undervalued
|
$18.71
|
477.6% Upside
|
Bargain
|
Weak
|
0.0%
|
November 18, 2026
|
1.3x
|
77.128 M
|
-14.891 M
|
1.8%
|
30.5%
|
1.2
|
93.1%
|
